ClinicalTrials.gg
Active, not recruitingNCT05723562AZUR-1Updated May 26, 2026

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

A Phase 2 interventional study of Dostarlimab in Neoplasms, Rectal, sponsored by GlaxoSmithKline. Active, not recruiting at 42 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 780 studies in Rectal Neoplasms with a site in United States — 81 open to participants now, 140 under way, 9 of them phase 3. Rectal Neoplasms · United States.

Enrollment
125th of 620
154 · median 39
Started
2023
with 18 others
Phase 2
232 of 780
21 open now
Primary completion
2026-11
later than 36 of 139 live
Registered
714th of 780
by date

Among the 780 studies in Rectal Neoplasms with a site in United States, this one is the 125th largest by enrollment of the 620 interventional ones that give a count, is one of 19 that started in 2023, is one of 232 in phase 2, reaches primary completion later than 36 of the 139 other live ones, and was the 714th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

81 of the 780 studies in Rectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 405 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 780 studies in Rectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective treatment that can allow participants to avoid chemotherapy, radiation, and surgery.

03

Conditions studied

  • Neoplasms, Rectal

Browse trials for

Keywords

  • JEMPERLI
  • dostarlimab-gxly
  • GSK4057190
  • Stage II/III rectal cancer
  • Neoadjuvant
  • dMMR
  • MSI-H
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has confirmed Stage II to III (T3-T4, N0, or T any, N+), locally advanced rectal cancer
  • Participant has radiologically and endoscopically evaluable disease.
  • Participant has a tumor which can be categorized as dMMR or MSI-H by local or central assessment

Exclusion criteria

Exclusion Criteria:

  • Participant has distant disease.
  • Participant has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer.
  • Participant has any history of interstitial lung disease or pneumonitis
  • Participant has experienced any of the following with prior immunotherapy: any imAE of Grade ≥3, immune-related severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or DRESS syndrome), or myocarditis of any grade. Non laboratory abnormalities are not exclusionary.
  • Participant has a known additional that progressed or required active treatment within the past 2 years. Exceptions include adequately treated superficial skin cancers, superficial bladder cancers, and other in situ cancers.
  • Participant has an active disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, , or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  • Participant has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or has known allergies to dostarlimab or its .
  • Has received or plans to receive an organ or stem cell transplant that uses donor stem cells ( stem cell transplant).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Dostarlimab monotherapy

    Biological: Dostarlimab

Interventions

  • BiologicalDostarlimab

    Dostarlimab will be administered.

    Also known as: JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190

06

What researchers measure

Primary outcomes

  1. Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR)

    cCR12 is achieved when a participant maintains complete clinical response (cCR) as assessed by ICR for 12 months following their post-intervention disease assessment (PIDA)

    Time frame: 18 Months

Secondary outcomes

  1. Number of Participants with Sustained Complete Clinical Response for 24 Months (cCR24) as assessed by ICR

    cCR24 is achieved when a participant maintains complete clinical response (cCR) as assessed by ICR for 24 months following their post-Intervention disease assessment (PIDA)

    Time frame: 30 Months

  2. Number of Participants with Sustained Complete Clinical Response for 36 Months (cCR36) as assessed by ICR

    cCR36 is achieved when a participant maintains complete clinical response (cCR) as assessed by ICR for 36 months following their post-Intervention disease assessment (PIDA)

    Time frame: 42 Months

  3. Number of Participants with Event Free Survival at 3 years (EFS3) as assessed by Investigator

    EFS3 is defined as participants who remained alive and free of disease progression precluding surgery, local recurrence, and distant recurrence at 3 years as assessed by Investigator

    Time frame: 3 years

  4. Event Free Survival (EFS) as assessed by Investigator

    EFS is defined as time from the date of first dose of study intervention to any of the following events: progression of disease that precludes surgery, local recurrence, distant recurrence (all as assessed by the investigator), or death due to any cause

    Time frame: Up to 74 months

  5. Number of Participants with cCR12 as assessed by Investigator

    cCR12 is achieved when a participant maintains complete clinical response (cCR) as assessed by Investigator for 12 months following their post-intervention disease assessment (PIDA)

    Time frame: 18 Months

  6. Number of Participants with cCR24 as assessed by Investigator

    cCR24 is achieved when a participant maintains complete clinical response (cCR) as assessed by Investigator for 24 months following their post-intervention disease assessment (PIDA)

    Time frame: 30 Months

  7. Number of Participants with cCR36 as assessed by Investigator

    cCR36 is achieved when a participant maintains complete clinical response (cCR) as assessed by Investigator for 36 months following their post-intervention disease assessment (PIDA)

    Time frame: 42 Months

  8. Objective Response Rate (ORR) assessed by ICR

    ORR is defined as number of participants achieving a partial response (PR), near complete response (nCR) or complete clinical response (cCR) at PIDA or at least 4 weeks but no longer than 8 weeks after PIDA for participants with nCR or incomplete clinical response (iCR) (PIDA 2) as assessed by ICR

    Time frame: Up to 33 Weeks

  9. Objective Response Rate (ORR) as assessed by Investigator

    ORR by Investigator, defined as achieving a PR, nCR, or cCR at PIDA or at least 4 weeks but no longer than 8 weeks after PIDA for participants with nCR or iCR

    Time frame: Up to 33 Weeks

  10. Organ Preservation Rate

    Organ Preservation Rate defined as not undergoing Total Mesorectal Excision (TME), either as primary management or for local recurrence, and who did not have a permanent colostomy created, at any time up to 3 years

    Time frame: 3 years

  11. Disease-Specific Survival (DSS)

    DSS is defined as time from the date of first dose of study intervention to death due to disease

    Time frame: Up to 74 months

  12. Disease-Specific Response at 5 years (DSS5)

    DSS5 is defined as the number of participants not dying due to disease under study at 5 years from the first dose of study intervention

    Time frame: Up to 5 years

  13. Overall Survival (OS)

    OS is defined as time from first dose of study intervention to death from any cause

    Time frame: Up to 74 months

  14. Overall Survival at 5 years (OS5)

    OS is defined as number of participants as being alive at 5 years from first dose of study intervention

    Time frame: Up to 5 years

  15. Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), Immune mediated Adverse Events (imAEs) based on Severity

    Time frame: Up to 74 months

  16. Number of Participants with discontinuation of study intervention

    Time frame: Up to 24 weeks

  17. Serum concentration of Dostarlimab

    Time frame: Up to 37 weeks

  18. Concentration at the end of infusion (C-EOI) of Dostarlimab

    Time frame: Up to 37 weeks

  19. Trough Concentration (C-trough) of Dostarlimab

    Time frame: Up to 37 weeks

  20. Number of Participants with Anti-Drug Antibodies against Dostarlimab

    Time frame: Up to 37 weeks

07

Study locations

42 sites
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87131, United States
  • GSK Investigational Site
    New York, New York 10022, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Dallas, Texas 75390, United States
  • GSK Investigational Site
    Richmond, Virginia 23298, United States
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 0C1, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • GSK Investigational Site
    Besançon, 25030, France
  • GSK Investigational Site
    Marseille, 13273, France
  • GSK Investigational Site
    Paris, 75012, France
  • GSK Investigational Site
    Pessac, 33604, France
  • GSK Investigational Site
    Rennes, 35000, France
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Dresden, 01307, Germany
  • GSK Investigational Site
    Düsseldorf, 40225, Germany
  • GSK Investigational Site
    Frankfurt, 60488, Germany
  • GSK Investigational Site
    München, 81377, Germany
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Padova, 35128, Italy
  • GSK Investigational Site
    Roma, 00168, Italy
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Kanagawa, 232-0024, Japan
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Osaka, 565-0871, Japan
  • GSK Investigational Site
    Utrecht, 3584 CX, Netherlands
  • GSK Investigational Site
    Seoul, 05505, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
  • GSK Investigational Site
    Seoul, 120-752, South Korea
  • GSK Investigational Site
    Seoul, 135-710, South Korea
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Granada, 18014, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Valencia, 46010, Spain
  • GSK Investigational Site
    Leeds West Yorkshire, LS9 7TF, United Kingdom
  • GSK Investigational Site
    London, EC1A 7BE, United Kingdom
  • GSK Investigational Site
    Sutton, SM2 5PT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2026, 42 months after the start.

Of 241 phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 75. This study's planned 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 10, 2023
StartActual
Apr 3, 2023
Primary completionEst.
Nov 2, 2026
CompletionEst.
Oct 11, 2029
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05723562
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Apr 3, 2023
Primary completion
Nov 2, 2026 (estimated)
Completion
Oct 11, 2029 (estimated)
Last update
May 26, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion